Feed GDRX
GD

GoodRx Holdings, Inc. GDRX NASDAQ · Healthcare · United States

$3.51 -1.40% -$0.05

Summary

50 / 100 · Bulios Score

What speaks for it

  • The share price is below the Bulios Fair Price.
  • Out of every 100 USD of revenue, 19 USD is left as free cash.
  • It bought back its own shares for $206.9M in the last fiscal year, 17% of its market value.

What to watch

  • Out of every 100 USD of revenue, only 2.1 USD is left as net profit.
  • Operating profit covers the interest on its debt only 2.0 times.
  • Revenue grew by only 1.3% a year over the last 3 years.
  • It earns only 2.6 USD a year on every 100 USD of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $3.51

By our assumptions the business is worth more than its shares cost today.

P/E today 73.7
Medical - Healthcare Information Services industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 73.7 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Slowly

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 7.7% a year over 5 years. Over the last 3 years it grew by 1.3% a year. For the next fiscal year analysts expect revenue to grow by 0.4%.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Medical - Healthcare Information Services) 5.7 USD

Out of every 100 USD of revenue, 2.1 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Mostly

Repaying all its debt would take 3.7 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $4.19 is 19% above today's price. 38% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2024

By product

By region

The company reports no revenue by region.

Prescription Transactions Revenue brings in 84% of revenue. Subscription Revenue grew fastest, by 13% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy